Related Experiment Video

Updated: Oct 7, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Cyclooxygenase-2: a target for the prevention and treatment of breast cancer

L R Howe1, K Subbaramaiah, A M Brown

  • 1Strang Cancer Research Laboratory, Rockefeller University, Box 231, 1230 York Avenue, New York, New York 10021, USA. lrhowe@med.cornell.edu

Endocrine-Related Cancer
|June 9, 2001
PubMed

Insights

Cyclooxygenase-2 (COX-2) overexpression drives tumor formation. Selective COX-2 inhibitors show promise for preventing and treating breast cancer, warranting clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Cyclooxygenase-2 (COX-2), an inducible prostaglandin synthase, is upregulated in various human cancers, including breast cancer.
  • COX-2 overexpression in the mammary gland is sufficient to induce tumor formation in animal models.
  • The role of COX-2 in tumorigenesis is well-studied in colorectal cancer and is being investigated for breast cancer.

Purpose of the Study:

  • To explore the potential utility of selective COX-2 inhibitors for breast cancer prevention and treatment.
  • To compare data from colon and breast cancers regarding COX-2's role.
  • To discuss mechanisms of COX-2 upregulation and its contribution to tumorigenesis.

Main Methods:

  • Review and comparison of existing data on COX-2 in colorectal and breast cancers.
  • Analysis of studies investigating COX-2 inhibitors in mammary tumorigenesis models.
  • Discussion of molecular mechanisms underlying COX-2's role in cancer.

Main Results:

  • COX-2 overexpression is implicated in breast cancer development.
  • Selective COX-2 inhibitors have demonstrated effectiveness in preventing and treating breast cancer in animal models.
  • Understanding COX-2 upregulation mechanisms is crucial for therapeutic strategies.

Conclusions:

  • Selective COX-2 inhibitors represent a potential therapeutic strategy for breast cancer.
  • Further clinical trials are necessary to validate the efficacy of COX-2 inhibition in human breast cancer.
  • COX-2's role in tumorigenesis provides a target for novel cancer therapies.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...